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Awareness of myocarditis in association with inflammatory bowel diseases is crucial as it bears a rare but serious
risk for mortality. This report describes the case of a young Caucasian male, whose heart biopsy was tested negative
for giant cells and bacterial or viral genomes or proteins. He was experiencing severe lymphocytic myocarditis
(other than mesalamine-induced) along with cardiogenic shock during ulcerative colitis exacerbation. This is an
extremely rare, if not unique, clinical constellation. We chose to study the epidemiologic grounds and all major
aspects of differential pathogenesis and treatment of this serious health problem.
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Awareness of myocarditis, pericarditis or myopericarditis
[1] in association with inflammatory bowel diseases
(IBD), e.g. ulcerative colitis (UC) and Crohn’s disease, is
crucial, as they convey a rare but serious risk for mortal-
ity. The onset of symptoms often occurs during IBD ex-
acerbation and prognosis varies from a mild cardiac
disorder to severe cardiogenic shock. To date, most of
the cases reported in association with IBD (other than
infectious or ‘giant cell’ myocarditis), consider the myo-
carditis as a side effect of mesalamine therapy [2].
Lymphocytic myocarditis as a pure extraintestinal mani-
festation of IBD is extraordinarily rare [3].Case presentation
A 30-year-old Caucasian male with a one-year history of
UC was admitted to our intensive care unit (ICU) due to
acute heart failure from an external hospital, where he
had presented with abdominal pain and bloody diarrhea
two weeks previously. These symptoms were assumed to
arise from UC exacerbation. Prednisone (1 mg/kg-body-
weight/day) and azathioprine (2 mg/kg-body-weight/
day) had been added to the standard therapy with mesa-
lamine (4 g/day). Ten days later, the patient rapidly* Correspondence: Varnavas.Varnavas@uk-essen.de
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unless otherwise stated.developed aggravated symptoms of left heart failure. A
transthoracic cardiac echocardiogram (TTE) confirmed
severe impairment of left ventricular (LV) function with
the ejection fraction (EF) approaching 15%, before the
patient was referred to our ICU.
On ICU admission, a 12-lead electrocardiogram (ECG)
detected sinus tachycardia of 100/min and non-specific
ST-T wave changes without any significant evidence of
acute myocardial ischemia. A chest X-ray showed no
pulmonary infection. TTE verified LV dysfunction with
advanced hypokinesia to akinesia of the basal/middle-in-
ferior/septal/anterior wall resulting in an EF of 13% and
revealed pericardial effusion (PE) of 1.6 cm (Figure 1A,B).
These findings were accompanied by abnormal laboratory
tests including anemia (hemoglobin: 7.6 g/dl), leukocytosis
(16.25/nl) and elevated levels of C-reactive protein (27.6
mg/dl), troponin-I (7.6 ng/ml), myoglobin (664 g/dl), brain
natriuretic peptide (4744.7 pg/ml), creatinine (1.43 mg/dl),
lactate dehydrogenase (565 U/l), aspartate aminotransfer-
ase (253 U/l), alanine aminotransferase (166 U/l) and
gamma-glutamyl transpeptidase (119 U/l). Table 1 shows
the initial as well as follow-up routine biochemistry pa-
rameters along with in-house-specific reference values.
Invasive blood pressure monitoring and pulmonary
artery catheterization (via a Swan-Ganz catheter) were
used to record hemodynamic variables. Subsequently,
dobutamine (15 μg/kg body weight/minute) was admin-
istered because of deranged cardiac output (1.8 l/min)al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Transthoracic cardiac echocardiogramms. At ICU admission: (A) long axis view, and (B) short axis view; both views show a pericardial
effusion of 1.6 cm. At ICU discharge: (C) long axis view, and (D) short axis view; both views confirm significant reduction of pericardial effusion.
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desirable tachycardia, the dobutamine was switched to
milrinone (0.75 μg/kg-body-weight/minute). On grounds
of insufficient inotropic drug efficacy in line with un-
changed cardiac output and cardiac index measurements
and echocardiographic findings, as well as lack of clinical
improvement, the use of an intra-aortic balloon pump
(ECG-triggered) was considered mandatory.
While no evidence of myocardial infarction or coronary
artery disease was found in the left heart, right cardiac
catheterization revealed an elevated mean pulmonary ar-
tery pressure of 33 mmHg (a mean value of 15 mmHg is
considered normal) and multiple myocardial biopsies were
acquired.
Histological examination revealed acute myocarditis
with lymphocytic infiltration. No neutrophile granulo-
cytes or giant cells were found (Figure 2A). Furthermore,
PCR analysis of the tissue did not detect any adenovirus
DNA, parvovirus B19 DNA, human herpesvirus 6 DNA,
Epstein-Barr virus DNA, varicella zoster virus DNA, her-
pes simplex virus DNA, cytomegalovirus DNA or entero-
virus RNA including Coxsackie A virus and Coxsackie B
(1-6) virus. In addition, immunohistochemical analysis did
not detect any cytomegalovirus-associated proteins. The
patient tested negative for HIV infection based on detec-
tion of specific antibodies (via ELISA) as well as RNA (via
PCR) in serum.In consideration of the patient’s critical condition and
the persistently high levels of serum inflammatory
markers, the patient was started on empiric antibiotic
coverage consisting of intravenous piperacillin/tazobac-
tam (3 × 4.5 g/day over 10 days).
While awaiting systemic infection (diagnostic) results,
azathioprine was paused. Further immunological and in-
fection parameters pertinent to myocarditis were mea-
sured: rheumatoid factor (negative, <10.3 IU/ml) and
antinuclear and anti-centromere antibody levels (ANA
negative, HEP2-IFT <1:80; c-ANCA and p-ANCA nega-
tive, ANCA-IFT <1:10). All blood cultures collected
within 3 days of admission were negative for bacterial
and fungal growth.
Nine days later, the intra-aortic balloon pump was re-
moved after gradual tapering off of milrinone accompan-
ied by normalization of hemodynamic parameters, e.g.
cardiac output was 8 l/min and cardiac index was 3.7 l/
min/m2. At day 15 of ICU treatment, a TTE confirmed
improved LV function with an EF of 50% as well as elimin-
ation of the PE (Figure 1C, D) and the patient was dis-
charged to a ward. At this point, cardiac magnetic
resonance imaging (MRI) was performed, which con-
firmed myocarditis along with tissue edema and moderate
PE (0.3 cm); however, no late enhancement was detected.
Subsequently, the heart failure therapy, i.e. bisoprolol (10
mg/day), ramipril (2.5 mg/day) and spironolactone








Leucocytes (WBCs) 16.25 9.11 8.71 6.78 3.6–9.2 /nl
Red Blood Cells (RBCs) 2.63 4.14 4.97 5.08 4.5–5.6 /pl
Hemoglobin (Hb) 7.60 12.00 14.30 14.6 13.7–17 g/dl
Hematocrit (Hct) 0.22 0.37 0.42 0.421 0.4–0.5 l/l
Mean Corpuscular Volume (MCV) 82.90 89.40 83.70 82.9 83–98 fl
Mean Corpuscular Hemoglobin (MCH) 28.90 29.00 28.80 28.7 28–33 pg
Mean Corpuscular Hemoglobin Concentration (MCHC) 34.90 32.40 34.40 34.7 32–36 g/dl
Platelets 499 321 263 224 140–320 /nl
Mean Platelet Volumen (MPV) 9.00 9.20 9.70 10.2 9.4–12.2 fl
Prothrombin Time (PT or Quick) 48 96 98 97 70–130 %
International Normalized Ratio (INR) 1.45 1.04 1.02 1.02
Activated Partial Thromboplastin Time (aPTT) 28.60 26.30 27.10 26.8 24.4–32 sec
Fibrinogen 557 448 566 386 210–400 mg/dl
Sodium 127 138 142 142 136–145 mmol/l
Potassium 5.60 4.80 4.60 4.7 3.5–5.1 mmol/l
Calcium 1.94 2.29 2.38 2.48 2.08–2.6 mmol/l
Magnesium 0.78 0.83 0.79 0.81 0.66–1.0 mmol/l
Phosphate 4.40 4.40 2.80 3.2 2.7–4.5 mg/dl
Creatinine 1.43 0.84 1.24 1.32 0.9–1.3 mg/dl
Blood Urea Nitrogen (BUN) 42.00 21.00 22.00 22 6–19.8 mg/dl
Creatinine Kinase (CK) 418 13 45 59 38–174 U/l
Creatinine Kinase –MB (CK-MB) 61 <25 U/l
Creatinine Kinase –MB% (CK-MB %) 15 %
Troponin I 7.60 0.04 0.42 0.08 0–0.1 ng/ml
Myoglobin 664 21 30 20 10–67 μg/l
Aspartat Aminotransferase (ASAT) 253 19 15 21 0– < 50 U/l
Alanine Aminotranseferase (ALAT) 166 40 28 42 <50 U/l
Gamma-glutamyl transpeptidase (GGT) 119 79 33 84 <55 U/l
Lactate dehydrogenase (LDH) 565 183 142 138 100–247 U/l
C-reactive protein (CRP) 27.60 0.70 4.10 0.6 <0.5 mg/dl
Brain natriuretic peptide (BNP) 4744.70 462.30 108.60 60.5 0–100 pg/ml
Glomerular Filtration Rate (GFR) (MDRD) 62 114 73 68 ml/min/1.73 q
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hemodynamic parameters and clinical improvement and
the patient was discharged after full recovery to ambulant
treatment. Of note, the systemic therapy with mesalamine
was never interrupted. Because of the active colitis, add-
itional systemic therapy with acetylsalicylic acid was not
taken into consideration after discharge from the hospital.
Six months after the first incident, the patient pre-
sented to our hospital with mild dyspnea on exertion
and slight abdominal pain without bloody diarrhea. On
admission, medication consisted of mesalamine (4 g/day)
and budesonide (rectal foam, 2 mg/day). His bloodpressure levels and serial ECG reports were normal. An
X-ray showed no pulmonary infection. A TTE revealed a
stable LV function (EF 50%); however, moderate PE (0.8
cm) was observed (Figure 3). Laboratory tests demon-
strated slight elevations of inflammatory parameters and
brain natriuretic peptide (Table 1). Thus, we promptly
assumed that the beginning of an UC re-exacerbation
might have triggered recurrent myocarditis. Unfortu-
nately, the patient declined colonoscopy. As expected, a
follow-up cardiac MRI revealed anterior LV wall edema
along with PE (1.2 cm) and lateral wall late enhancement,
indicative of acute myocarditis (Figures 4, 5 and 6). Again,
A 





Figure 2 Histology images revealed acute myocarditis with lymphocytic infiltration and moderate myocyte apoptosis at first onset (A)
and relapse (B). These biopsies did not detect giant cells or significant neutrophile infiltrates.
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same pattern of lymphocytic myocarditis (Figure 2B). This
time, the patient’s clinical condition improved on adminis-
tering prednisone (1 mg/kg-body-weight/day), bisoprolol
(10 mg/day), ramipril (2.5 mg/day) and spironolactone
(25 mg/day). After discharge, a 6-month follow-up TTE
showed normal LV function and no PE.
Conclusions
An association of cardiac disease with IBD has rarely been
found [2]. In a large nationwide study of IBD patients
(N = 15,572) conducted from 1977 to 1992 in Denmark,
the incidence of myocarditis was 0.03% [2]. In these cases,
the most frightening scenario is finding giant cells in a bi-
opsy. Giant cell myocarditis, which often coincides withFigure 3 Transthoracic cardiac echocardiogramms. (A) Long axis view.
at readmission.autoimmune diseases, has been reported as inevitably fatal
with a fulminate course resulting in death, usually within
3 months [4-6]. To date, less than five cases have been re-
ported in the literature of IBD-related myocarditis (other
than giant cell myocarditis) that rapidly ends in severe
heart failure during UC exacerbation for either new onset
or relapse cases. This convinced us of the need to report
this case of a young male experiencing severe lymphocytic
myocarditis along with left heart failure during UC
exacerbation.
Lymphocytic myocarditis emerges through an intersti-
tial influx of lymphocytes followed by consecutive myo-
cyte apoptosis [4]. Apparently, lymphocytic infiltrates
have been observed in most cases of biopsy-verified
myocarditis. Of these, the positive detection of(B) Short axis view. These views show a pericardial effusion of 0.8 cm
Figure 4 Cardiac magnetic resonance imaging (MRI), turbo inversion recovery magnitude (TIRM) sequence. (A) Edema in anterior wall.
(B) Pericardial effusion of 1.2 cm.
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in myocardial biopsy specimens or bacterial or fungal
systemic infections represent the most trivial findings in
patients experiencing active IBD-related lymphocytic
myocarditis (reviewed in [3,4,7]). Biopsy results for our
patient were negative for viral genomes or proteins. No
bacterial or fungal infections were found in peripheral
blood during all stays or follow-up visits in our hospital.
Azathioprine was paused on first admission to the ICU
as it is of unproven benefit for myocarditis other than
for giant cell myocarditis [4]. Therefore, both timesFigure 5 Cardiac magnetic resonance imaging (MRI), balanced steady
pericardial effusion of 1.2 cm.acute phase immunosuppressive therapy was confined to
systemic therapy with prednisone [7-9]. Because of the
symptoms of co-emergent severe colitis, systemic therapy
with prednisone was considered mandatory. In any other
case, intrapericardial treatment with triamcinolone, espe-
cially in patients with perimyocarditis, would be an
equally effective local therapy option [10]. Interestingly,
6 months after the first incident, the patient’s cardiac
function deteriorated after discontinuation of prednisone
[7] (Figure 7). This event had clinical, TTE, MRI and
histological evidence of recurrent myocarditis, which-state free precesion (bSSFP) sequence. (A-C) These images show
Figure 6 Cardiac magnetic resonance imaging (MRI), inversion recovery (IR) turbo fast low-angle shot (FLASH) sequence. (A) Beginning
enhancement in lateral wall. (B-C) Intramural late-enhancement in lateral wall.
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therapy and is consistent with data published elsewhere
[7].
IBD-related cardiac disease may also occur as mesalamine-
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Figure 7 Medication curves. The graph illustrates dose and application tim
and local therapy with budesonide during the entire observation period. This
colitis along with emergence of myocarditis symptoms.eosinophilic infiltration can be observed on a biopsy, has
previously been described as a mechanism of drug hyper-
sensitivity, and the symptoms are milder [11]. Here,
mesalamine-induced myocarditis is unlikely since mesala-















e of systemic treatment with prednisone, azathioprine and mesalamine
graph also indicates the time points of clinical exacerbation of ulcerative
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these episodes of myocarditis were due to mesalamine [12].
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